(Q48398320)

11 February 2018

title

Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease. (English)

1 reference

11 February 2018

1 reference

Wilhelm Kuker

8

0 references

Angela Vincent

14

object named as

Angela Vincent

1 reference

11 February 2018

17

Jacqueline Palace

1 reference

11 February 2018

1

Maciej Juryńczyk

1 reference

11 February 2018

author name string

George Tackley

2

1 reference

11 February 2018

Yazhuo Kong

3

1 reference

11 February 2018

Ruth Geraldes

4

1 reference

11 February 2018

Lucy Matthews

5

1 reference

11 February 2018

Mark Woodhall

6

1 reference

11 February 2018

Patrick Waters

7

1 reference

11 February 2018

Matthew Craner

9

1 reference

11 February 2018

Andrew Weir

10

1 reference

11 February 2018

Gabriele C DeLuca

11

1 reference

11 February 2018

Stephane Kremer

12

1 reference

11 February 2018

Maria Isabel Leite

13

1 reference

11 February 2018

Anu Jacob

15

1 reference

11 February 2018

Jérôme de Sèze

16

1 reference

11 February 2018

language of work or name

English

0 references

publication date

8 October 2016

1 reference

11 February 2018

Journal of Neurology, Neurosurgery and Psychiatry

published in

1 reference

11 February 2018

volume

88

1 reference

11 February 2018

issue

2

1 reference

11 February 2018

page(s)

132-136

1 reference

11 February 2018

Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers

cites work

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2016-314005

Failure of natalizumab to prevent relapses in neuromyelitis optica.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2016-314005

Revised diagnostic criteria for neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2016-314005

Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2016-314005

Overlapping CNS inflammatory diseases: differentiating features of NMO and MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2016-314005

Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2016-314005

MRI characteristics of neuromyelitis optica spectrum disorder: an international update

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2016-314005

Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2016-314005

Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2016-314005

MOG cell-based assay detects non-MS patients with inflammatory neurologic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2016-314005

The Measurement of Observer Agreement for Categorical Data

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2016-314005

Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2016-314005

Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2016-314005

Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2016-314005

Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2016-314005

Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2016-314005

Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2016-314005

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2016-314005

21 January 2018

Identifiers

DOI

10.1136/JNNP-2016-314005

1 reference

11 February 2018

1 reference

11 February 2018